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1120A 32-year-old man presented with exertional dyspnea 14 months
after an episode of pericarditis. On admission, an electrocardiogram
was abnormal with prominent ST-segment elevation, abnormal Q
waves, and inverted T waves in leads II, III, and aVF (Fig. 1A).
Selective coronary angiography revealed an abrupt occlusion of the
proximal portion of right coronary artery (RCA) with an aneu-
rysmal dilation of the proximal RCA (Fig. 1B). The cardiac en-
zymes were not elevated. A recent Q-wave myocardial infarction of
uncertain age was considered. The erythrocyte sedimentation rate at
70 mm/h and C-reactive protein at 1.28 mg/dl were found to
be abnormal. The patient had no clinical evidence suggestive of
Kawasaki disease, Takayasu arteritis, immunoglobulin G4–related
pathology, and autoimmune or collagen vascular disease. The
remaining laboratory tests revealed dyslipidemia with serum tri-
glycerides level of 224 and high-density lipoprotein cholesterol level
of 25 mg/dl. A contrast-enhanced multislice computed tomography
(CT) angiography demonstrated an RCA aneurysm and intense
contrast effect of intravenous contrast media in the aneurysm
(Fig. 1C). The FDG PET/CT scan of the current patient
demonstrated a focal FDG uptake at the aneurysmal site in the
RCA (Fig. 1C). A treatment with pitavastatin 4 mg/day
was initiated. After a 3-month treatment of pitavastatin, high-
density lipoprotein cholesterol level remarkably increased by 46%
(from 25 to 37 mg/dl), whereas low-density lipoprotein cholesterol
level remained unchanged (from 61 to 65 mg/dl). Serum levels of
inﬂammatory biomarkers were decreased by about 50% (C-reactive
protein: 1.28 to 0.61 mg/dl; erythrocyte sedimentation rate: 70 to
38 mm/h). CT angiography at 3 months demonstrated an atten-
uation of intense contrast effect in the RCA aneurysm (Fig. 1C),
and the FDG PET/CT scan revealed almost complete resolution of
abnormal FDG uptake in the aneurysm (Fig. 1C). The current
report is encouraging in that prospective and serial imaging even in
coronary artery inﬂammation may become possible in the future.
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Idiopathic From Pulmonary
Hypertension Due to HFpEF
There has been increasing recognition of pulmonary hypertension
(PH), which develops as a direct consequence of impaired left
ventricular distensibility and relaxation, described as PH due to
heart failure with preserved ejection fraction (PH-HFpEF) (1).
Current guidelines emphasize the importance of distinguishing PH-
HFpEF from idiopathic pulmonary arterial hypertension (IPAH), a
rare disease caused by progressive luminal obliteration of small
pulmonary arteries (2). At present, right heart catheterization
(RHC) is the deﬁnitive investigation to conﬁrm the diagnosis. In
this prospective study, we explored the use of cardiac magnetic
resonance (CMR)–derived left atrial volume (LAV) as a simple,
noninvasive method for distinguishing IPAH from PH-HFpEF,
without the need for additional variables or derived equations.
Consecutive treatment-naive patients with a suspected new diag-
nosis of pulmonary hypertension underwent diagnostic assessment
between January 2009 and March 2011. Patients with clear evidence
of an underlying cause of pulmonary hypertension such as chronic
thromboembolic disease, connective-tissue disease, left ventricular
(LV) systolic dysfunction, or signiﬁcant valvular heart disease on
echocardiography were excluded.
CMR imaging was performed in the supine position on a 1.5-T
magnetic resonance imaging scanner and images were analyzed
using the Argus analysis software (Houston, Texas). CMR images
were fully analyzed prior to RHC, but the analyzer was blinded to
the catheterization results. LAV was determined using standard 2-
and 4-chamber views and the biplane area-length method. Mea-
surements were made in accordance with previously published
methods (3).
RHC was performed within 72 h of CMR, with the patient in a
supine position breathing room air. Cardiac output was determined
using thermodilution. Following RHC, the diagnosis of IPAH or
PH-HFpEF was made according to current guidelines (2).
After RHC, 37 patients were diagnosed with IPAH, 21 patients
with PH-HFpEF, and 23 patients were found not to have pulmonary
hypertension. The IPAH group was younger, had lower systemic
blood pressure, and a lower incidence of diabetes mellitus and atrial
ﬁbrillation than the PH-HFpEF group did.
At CMR, in comparison to PH-HFpEF, IPAH patients had
increased right ventricular dilation, reduced right ventricular func-
tion, impaired LV ﬁlling, and lower left atrial volume (24  9 ml/m2
vs. 67  20 ml/m2, p < 0.0001) (Fig. 1).
Receiver-operating characteristic analysis of CMR-derived vari-
ables that differed between IPAH and PF-HFpEF demonstrated
that LAV was the most sensitive and speciﬁc variable to discrimi-
nate between the two conditions. Using a threshold LAV of
<43 ml/m2, IPAH could be distinguished from PH-HFpEF with
97% sensitivity and 100% speciﬁcity, with area under the receiver-
operating characteristic curve of 0.990.
With the global increase in hypertension, coronary artery disease,
and diabetes, PH-HFpEF is becoming more prevalent. One of
the most important diagnostic challenges for a pulmonary vascular
center is to distinguish IPAH from PH-HFpEF, particularly
since the emergence of PAH-speciﬁc therapies. These treatments
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Figure 1. LAV Was Signiﬁcantly Lower in IPAH Than in PH-HFpEF
Only 1 idiopathic pulmonary arterial hypertension (IPAH) patient had a left
atrial volume (LAV) >43 ml/m2. Dotted pink line represents the LAV threshold
of 43 ml/m2. PH ¼ pulmonary hypertension; PH-HFpEF ¼ pulmonary hyper-
tension due to heart failure with preserved ejection fraction.
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1121are expensive, potentially dangerous, and current guidelines
recommend their use in IPAH, but not in PH-HFpEF, where they
are harmful (2).
In HFpEF, there is preserved LV systolic function, but impaired
diastolic function with abnormal LV relaxation and increased LV
ﬁlling pressure. Sustained elevations of LV diastolic ﬁlling pressures
will result in enlargement of the thin-walled left atrium, allowing
LAV to be used as a marker of the severity and chronicity of dia-
stolic dysfunction (4). Thenappan et al. (1) noted echocardiographic
left atrial enlargement in 64% of their PH-HFpEF group and only
18% of the PAH group, but they used multiple variables requiring
clinical, hemodynamic, and echocardiographic data to distinguish
between these conditions.
We acknowledge that echocardiography will give a measure of
LAV, but note the following limitations: 1) echocardiography un-
derestimates CMR-derived LAV, in both healthy subjects and pa-
tients with cardiovascular disease; and 2) CMR can be used when
acoustic windows are poor (3). We have shown that a single,
noninvasive, CMR-derived variable, LAV of <43 ml/m2, will
distinguish IPAH from PH-HFpEF, which is attractive for busy
pulmonary vascular centers.
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Temporal Course of Vessel
Healing and Neoatherosclerosis
After DES Implantation
Recently, late drug-eluting stent (DES) failure has become a po-
tential cause for concern following ﬁrst-generation DES implanta-
tion. Although these phenomena may result from multiple etiologic
factors, emerging evidence consistently suggests the importance of
delayed arterial healing and neoatherosclerosis progression as major
contributors. In vivo assessment of long-term vessel healing after
sirolimus-eluting stent (SES) deployment is limited, and the inci-
dence and process of in-stent atheroma formation remain unknown.
Although SES is no longer used in our clinical practice, many
patients have already undergone SES implantation, and a clear un-
derstanding of the long-term status of vessel reaction after stenting is
of clinical importance. Hence, this optical coherence tomography
(OCT) examination focusing on features inside the SES was per-
formed to elucidate neointimal changes during an extended period
(5 years) by comparing mid-phase and late-phase OCT ﬁndings.
From the Kobe University Hospital OCT database, 87 patients
underwent mid-phase (3 to 12 months) coronary angiography and
OCT examination after SES (Cypher, Cordis Corp., Miami Lakes,
Florida) implantation between October 2004 and January 2008. The
patients with target lesion revascularization before late-phase follow-
up were excluded from this study.
Quantitative OCT measurements were done as previously re-
ported (1). Peri-strut low intensity area (PLIA) was deﬁned as the
region around stent struts with a homogeneous lower intensity
compared with the surrounding areas, without signiﬁcant attenuation
(1). Extra-stent lumen was deﬁned as an external lumen behind the
stent struts (2). Intrastent thrombus was deﬁned as a mass protruding
beyond the stent strut into the lumen with signiﬁcant attenuation
behind the mass. Atherogenic neointima (AN) was deﬁned as neo-
intima containing a diffuse border and signal-poor region with
invisible struts underneath due to the marked signal attenuation.
The late-phase (36 to 80 months) follow-up was performed in
62 stents from 46 patients (66.9  7.8 years of age; 85% male).
Percentages of patients with hypertension, dyslipidemia, and dia-
betes mellitus were 96%, 87%, and 61%, respectively. A total of
912 matched OCT cross-sections were analyzed. Median neo-
intimal thickness increased from 82.5 mm (interquartile range
[IQR]: 65 to 117 mm) to 120.7 mm (IQR: 87 to 167 mm; p ¼ 0.006).
